Introduction
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is observed in peripheral neuropathies including Guillain-Barré syndrome, and acute autonomic and sensory neuropathy (1) (2) (3) . However, there have been no reports of chronic inflammatory demyelinating polyneuropathy (CIDP) complicated with SIADH. Here, we report a case of CIDP with SIADH.
Case Report
A 54-year-old man developed muscle weakness and numbness in all four extremities in 1999. He was admitted to another hospital, and diagnosed as having polyneuropathy. His symptoms disappeared soon with oral administration of prednisolone (PSL). However, his muscle weakness and numbness relapsed when PSL was tapered. He was referred to our hospital in October 2001. He was diagnosed as having CIDP, and given intravenous immunoglobulin (IVIg) at a daily dosage of 20 g for five days. Two weeks later, he recovered and could walk independently. He was given PSL at a dosage of 30 mg for the prevention of relapse upon discharge. On June 27, 2002, he felt severe back pain after PSL had been tapered to 15 mg every other day. Thereafter, muscle weakness and numbness reappeared in all limbs. On the second admission, his mental status and cranial nerve function were normal. However, muscle weakness of his arms (Manual Muscle Test [MMT] grade 4) and legs (MMT grade 3) was recognized. All deep tendon reflexes were absent. Vibratory and position sense was impaired in the feet. Touch, temperature, and pinprick sensation was mildly disturbed in a glove-stocking distribution. Coordination was clumsy in all limbs. He could not walk because of sensory ataxia and muscle weakness. Orthostatic hypotension and urinary retention were also observed.
Routine laboratory tests were normal except for decreased serum Na concentration (122 mEq/l; normal value 138-145 mEq/l) and elevated serum CPK concentration (811 IU/l; normal value 49-273 IU/l). Serum concentration of immunoglobulins was within the normal range. Anti-ganglioside antibodies, anti-DNA antibodies and anti-tumor markers were not detected. Although there was no sign of intracranial hypertension, an opening pressure of lumbar puncture was 215 (Table 1) , the amplitude and motor nerve conduction velocities were mildly reduced in all four limbs. Sensory nerve action potentials could not be recorded. Electrocardiogram, chest X-ray and brain MRI were normal. Although serum osmolality was decreased to 247 mOsm/l, urine osmolality was 675 mOsm/l and urinary sodium concentration was 175 mEq/l. Renal function, thyroid hormones and adrenal hormones were normal. Serum level of antidiuretic hormone (ADH) was remarkably elevated (5.52 pg/ml; normal value 0.3-4.2 pg/ml). Therefore, he was diagnosed as having a relapse of CIDP complicated with SIADH. On July 1, 2002, IVIg therapy (400 mg/kg/day for 5 days) was started. However, his muscle weakness and sensory impairment rapidly worsened, and quadriplegia (MMT grade 1) and somnolence ensued requiring mechanical ventilation for respiratory failure 5 days after the IVIg therapy had been started. Arterial blood gas analysis showed pH 7.34, PaO2 60.1 Torr, PaCO2 55.7 Torr and HCO3 29.2 mEq/l. Methylprednisolone pulse therapy (1,000 mg/day for 3 days) was therefore added and followed by PSL at a daily oral dosage of 60mg. However, his symptoms were not improved. On the 19th day, his lumbar puncture revealed CSF protein was markedly elevated to 1,315 mg/dl and serum Na concentration was still at a low level (123 mEq/l). On the next day, methylprednisolone pulse therapy was started again. His quadriplegia was gradually recovered to MMT grade 2 and the mechanical ventilation was stopped on the 40th day. On the 70th day, he could sit in a wheelchair by himself, and sensory impairment and autonomic dysfunction were also improved (Fig. 1) . 
Discussion
It is well known that SIADH results from several nervous system disorders. Among them are stroke, brain tumor, sinus thrombosis, meningitis, Shy-Drager syndrome and peripheral neuropathy. In regard to peripheral neuropathy, SIADH might be associated with Guillain-Barré syndrome (1, 2), acute autonomic and sensory neuropathy (3), and paraneoplastic autonomic and sensorimotor neuropathy (4) .
The present case had a recurrent history of polyneuropathy since 1999. His CSF protein was markedly elevated without pleocytosis. His motor nerve conduction velocities were attenuated and sensory nerve action potential were not recordable. Therefore, he was diagnosed as CIDP based on the criteria by the Ad Hoc subcommittee of the American Academy of Neurology (5) . Moreover, on the present admission, he had acute aggravation of CIDP complicated with SIADH. To our knowledge, this is the first report of CIDP with SIADH. Lambert-Eaton syndrome and paraneoplastic polyneuropathy with pulmonary small cell carcinoma are often associated with SIADH, where ADH is inappropriately secreted by cancer cells. However, the pathogenic mechanism of SIADH in peripheral neuropathy is undetermined. In the previous reports, most of polyneuropathies with SIADH were accompanied by severe autonomic dysfunction (3, 4) . It is therefore likely that a lesion in the afferent baroregulatory pathway may be one of the causes (4). In contrast, damage of neurons around hypothalamus or intracranial hypertension is thought to be a possible cause of SIADH seen in meningitis, stroke and hydrocephalus (6) (7) (8) . So, intracranial hypertension may be another cause of SIADH in the present case.
Generally, symptomatic autonomic dysfunction is rare in patients with CIDP (9) . However, the present case presented with not only acute aggravation of CIDP with autonomic dysfunction but also intracranial hypertension associated with increased CSF protein. Therefore, it is likely that injury of the afferent fibers of the baroregulatory pathway or intracranial hypertension might have led to SIADH in this patient.
